PerpEquities

Equity · Healthcare

Humana Inc. (HUM) perpetual futures

Humana Inc. is a US health and well-being company providing medical and supplementary insurance plans, Medicare- and Medicaid-related programs, and healthcare services such as pharmacy management and home health care.

-1.3%NYSE closed
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NYSE:HUM

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

0/1 live markets
Venues
1
Live markets
0/1
24h volume
-
Open interest
-
Best liquidity
-
Tightest spread
-
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
OI / float
-
Spot performance
1D-1.41%
5D-0.99%
1M+1.80%
6M+67.07%
YTD+60.68%
1Y+63.89%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeHUM-USDTWatchlist------USDT-
Best venues for this underlying

Best liquidity

-
No live data-

Tightest spread

-
No live data-

Highest volume

-
No live data-

Company financials

Financials at a glance

Last report Q2 '26 · filed 2026-07-29 · next report 2026-11-06 · Updated 3m ago
All financials →

Valuation & key figures

Market cap
$49.4B
Updated 3m ago
Revenue
$154.2B
Trailing 12 months
Revenue growth
+25%
Next fiscal year
Profit margin
+0.8%
P/E
39.6
Peer P/E 22.8
P/S
0.3
Peer P/E
22.8
Similar listed perps
Free cash flow
$3.1B
Trailing 12 months
Net income
$1.2B
Trailing 12 months
Revenue estimate
$162.6B
Next fiscal year
Earnings
2026-11-06
Revenue est. $40.9B · Updated 3m ago
Dividend
$0.885
2026-12-24
Revenue (TTM)$146B+18.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)1.4%-0.3 pp vs a year agoOperating income $2.02B
Net income (TTM)$1.28B-18.9% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$443M-118.2% vs a year agoCapex $590M
Diluted EPS (TTM)$10.56-19.0% vs a year agoSum of the last 4 quarters
Net cash$9.62B+212.6% vs a year agoCash + short-term investments - debt
  • Last report (2026-07-29): revenue beat by 0.7%, EPS beat by 4.7%Revenue $40.9B vs $40.6B expected (+0.7%); EPS $7.61 vs $7.27 (+4.7%).
  • Revenue growth accelerating: 26.2% year on yearQ2 '26 revenue $40.9B, against an average of 13.9% over the four quarters before.
  • Operating margin 1.4% (TTM), -0.3 pp on a year agoOperating income grew -4.0% while revenue grew 18.3%.
  • 25.3% of pre-tax profit is eaten by non-operating lossesPre-tax income $1.61B vs operating income $2.02B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Revenue by business line

latest quarter
LineRevenuey/yShare
Insurance$39.1B–95.8%
Insurance Segment–––
CenterWell$6.79B–16.6%
CenterWell Segment–––
Eliminations/ Corporate-$5.06B–-12.4%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 282 lines Humana Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2026-11-06
Revenue est. $40.9B · Updated 3m ago
Dividend
$0.885
2026-12-24
  • Earnings today · Before market open

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20269.16$162.6B+25%16
FY 202717.00$167.8B+29%15
FY 202830.52$180.4B+39%9
FY 202934.91$189.5B+46%3
FY 203035.53$204.6B+58%3
Q1 202712.39$41.5B+5%8

Company events

6
2026-12-24Dividend$0.885-
2026-11-06Earnings · Before market openActual -0.7 / Estimate -1Beat
2026-10-30Dividend$0.885-
2026-07-29EarningsActual 7.61 / Estimate 7.27Beat
2026-06-26Dividend$0.885-
2026-04-29EarningsActual 10.31 / Estimate 10.24Beat

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
ARGX$51.7B8.630.4+32.9%1NTRA$52.4B18.0-319.1-5.7%2HENGRUI$46.3B9.435.9+27.0%1IDXX$52.8B11.345.2+25.4%1WUXIAPPTEC$52.9B6.115.6+45.5%1BEIGENE$43.6B7.127.9+10.7%1RVMD$38.1B192.7-19.4-946.8%1BSX$60.8B2.917.7+16.6%3

Company data

Company intelligence

Updated: Nov 2, 2026, 04:43 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Healthcare Plans
Chief executive
James A. Rechtin
Employees
67,060
IPO date
Dec 31, 1981
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei4.58
Piotroski scorei7/9
Overall ratingiB
Owner earningsi-$282.01M-$2.33 per share
ESG risk ratingiBIndustry rank: 2 out of 15

Rating factors

Return on equityi
3
Return on assetsi
3
Debt to equityi
1
Price to earningsi
2
Price to booki
3

Company press releases

Humana Board Declares Payment of Quarterly Dividend to StockholdersBusiness WireDid Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWireHumana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care ClinicsBusiness WireHumana Inc. to Release Third Quarter 2026 Results on November 6, 2026Business WireHumana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027Business WireHumana Inc. (NYSE: HUM) Investor Alert: Securities Fraud Case Moves Forward Following 22% Stock Drop; Schubert Jonckheer InvestigatingPRNewsWire

Congressional disclosures

Senate

House

Market cap history
$49.82B+10.7%Aug 26 – Oct 26
$45.01B$48.56B$52.11BHigh: $52.11B · 2026-10-12Low: $45.01B · 2026-08-03Latest: $49.82B · 2026-10-30Aug 26Sep 26Oct 26
Latest: $49.82B · 2026-10-30High: $52.11B · 2026-10-12Low: $45.01B · 2026-08-03
Largest fund holders
FundWeightShares held
VCPA.S0.16%7.5M
FLCB0.13%4.2M
VTI0.06%3.8M
VOO0.07%3.2M
FLCO0.56%3M
VO0.45%2.6M
VSCA.S0.06%2M
IVV0.08%1.6M
XSP.TO0.07%1.6M
SPY0.08%1.5M
FXAIX0.07%1.4M
VTV0.17%1.1M

Analyst track record

How the analysts covering HUM have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings150453
Analysts2634
Buy / hold / sell61 / 81 / 8202 / 240 / 11
Upgrades / downgrades / initiations12 / 5 / 016 / 17 / 9
Price targets hit / missed99 / 39 (72%)340 / 83 (80%)
Avg. return after a rating (TipRanks)+40.8%+65.5%
Best / worst call+181.1% / -34.2%+15,317.6% / -35.9%

After buy calls on this stock: median 21-day move +0.4% vs S&P 500 -3.1% (n = 204)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Ann HynesMizuho Securities85% hit rate on this stock · 13 targets measuredBuytarget $495Oct 13, 2026
  2. Michael WiederhornOppenheimer70% hit rate on this stock · 10 targets measuredBuytarget $475Oct 9, 2026
  3. Lance WilkesBernstein69% hit rate on this stock · 13 targets measuredBuytarget $425Oct 5, 2026

Latest ratings

DateAnalystCallTarget
Oct 20, 2026Jason CassorlaGuggenheimBuyMaintained$471article ↗
Oct 14, 2026Andrew Mok CFABarclaysBuyMaintained$582article ↗
Oct 14, 2026Andrew Mok CFABarclaysBuyMaintained$582
Oct 13, 2026Elizabeth Anderson CFAEvercore ISIBuyMaintained$480article ↗
Oct 13, 2026Ann HynesMizuho SecuritiesBuyMaintained$495article ↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$200$250$300$350$400$450Dec 25 · Buy 9 · Hold 15 · Sell 1Dec 25Jan 26 · Buy 8 · Hold 14 · Sell 1Feb 26 · Buy 7 · Hold 14 · Sell 2Feb 26Mar 26 · Buy 7 · Hold 14 · Sell 2Apr 26 · Buy 6 · Hold 13 · Sell 2Apr 26May 26 · Buy 8 · Hold 13 · Sell 2Jun 26 · Buy 8 · Hold 12 · Sell 2Jun 26Jul 26 · Buy 12 · Hold 11 · Sell 2Aug 26 · Buy 12 · Hold 12 · Sell 1Aug 26Sep 26 · Buy 12 · Hold 11 · Sell 1Oct 26 · Buy 16 · Hold 7 · Sell 1Oct 26Nov 26 · Buy 16 · Hold 7 · Sell 1Dec 25 · avg. target $291Jan 26 · avg. target $291Feb 26 · avg. target $229Mar 26 · avg. target $223Apr 26 · avg. target $227May 26 · avg. target $263Jun 26 · avg. target $286Jul 26 · avg. target $412Aug 26 · avg. target $420Sep 26 · avg. target $422Oct 26 · avg. target $462Nov 26 · avg. target $462Dec 25 · month-end close $256Jan 26 · month-end close $195Feb 26 · month-end close $191Mar 26 · month-end close $173Apr 26 · month-end close $236May 26 · month-end close $305Jun 26 · month-end close $397Jul 26 · month-end close $364Aug 26 · month-end close $383Sep 26 · month-end close $382Oct 26 · month-end close $415Nov 26 · month-end close $415

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 3, 2026 · 150 ratings

Other Healthcare perps

Embed this asset

HUM perpetuals · perpequities.comHUM perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/hum-perp"><img src="https://perpequities.com/badge/hum-perp.svg" width="240" height="64" alt="HUM perpetuals · perpequities.com" loading="lazy"></a>

Raw data: JSON · CSV · API

Next step

Stay on top of HUM perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for HUM — one email every Sunday.

Watchlist and alerts

Price and funding alerts for HUM, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X